Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs ResMed Inc. — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.47 (market cap $41.13B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: iShares 7-10 Year Treasury Bond ETF is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and ResMed Inc. for 51 Days on average.
| IEF | RMD | |
|---|---|---|
Market Cap | $41.13B | $31.89B |
Volume | 10,340,382 | 618,314 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $277.88 |
52-Week Low | $88.92 | $182.82 |
Typical Hold Time | 108 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.11, down 0.02% with a bearish technical outlook. The fund shows neutral oscillators but bearish moving averages, with RSI levels below 30 indicating potential oversold conditions. Recent dividend payments of $0.31-$0.33 provide income support amid market volatility. The bond market faces pressure from rising Treasury yields and inflation concerns.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current yields offer attractive entry points for income investors, persistent inflation and Fed policy uncertainty pose significant risks. Defensive positioning in fixed income suggests limited near-term upside potential.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
